GSK•benzinga•
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?
Summary
Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a favorable safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga